RHYTHM PHARMACEUTICALS, INC.
RYTMDrugs in Pipeline
7
Phase 3 Programs
4
Upcoming Catalysts
3
Next Catalyst
Sep 30, 2026
18wMarket Overview
Stock performance and key metrics
4 upcoming, 1 past
FDA PDUFA Date IMCIVREE (priority)
For Obesity caused by genetic deficiencies. NDA filing. Extracted from SEC filing: 8-K
Source3 more catalysts beyond 14 days
Start a 48h free trial to see all upcoming catalysts
Class I or III Antiarrhythmic Medications
Atrial Fibrillation
Setmelanotide
Genetic Obesity
Flecainide or Sotalol or Propafenone
Paroxysmal Atrial Fibrillation
Setmelanotide 2 mg
Bardet-Biedl Syndrome
Part C: RM-718
Hypothalamic Obesity
LB54640
Hypothalamic Obesity
Diuretics
Heart Failure
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Class I or III Antiarrhythmic Medications | Phase 3 | Atrial Fibrillation | - | - |
Setmelanotide | Phase 3 | Genetic Obesity | - | - |
Flecainide or Sotalol or Propafenone | Phase 3 | Paroxysmal Atrial Fibrillation | - | - |
Setmelanotide 2 mg | Phase 3 | Bardet-Biedl Syndrome | - | - |
Part C: RM-718 | Phase 2 | Hypothalamic Obesity | - | - |
LB54640 | Phase 2 | Hypothalamic Obesity | - | - |
Diuretics | Phase 2 | Heart Failure | - | - |